Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, et al. Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer. PLoS One 2021;16:e0261994.
PMID: 34941969